Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138430 | 1.00 | SLC9A1 (0.37) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4692589 | 1.00 | SLC9A1 (0.37) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4138433 | 0.88 | SLC9A1 (0.38) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4151419 | 0.84 | TSHR (0.36) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4151415 | 0.84 | TSHR (0.36) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4151420 | 0.84 | TSHR (0.36) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4142488 | 0.83 | SLC9A1 (0.41) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4142485 | 0.83 | SLC9A1 (0.41) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL4142493 | 0.83 | SLC9A1 (0.41) | SLC9A1SLC9A2KEAP1NFE2L2RIPK2 | |
| SCHEMBL5187351 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569935-B1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2008-08-20 | — | — | EP | claimed |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2009-01-15 | — | — | US | disclosed |
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1569935-B1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | SLC9A1 1418/4885SLC9A2 2534/4885KEAP1 1674/4885 |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | GAA, GANAB, ALPI | SLC9A1 1865/4885SLC9A2 2622/4885KEAP1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.